ODESA. UKRAINE. A NEW HORIZON IN MEDICINE.

Science thatadvances life.

A new-generation medical isotope cluster. From in-house isotope production to precision diagnostics.

Investment concept · Odesa, Ukraine. Project parameters
€80mplanned investment
8PET/CT scanners in the project
4,000+patients a year · planned capacity
300 kmtarget supply radius

Four disciplines. One shared ambition.

Isotopes. Diagnostics. Research. Digital health.

B2B

Production cluster

An industrial cyclotron and radiochemistry facilities for radiopharmaceuticals based on fluorine-18 and gallium-68. The plan covers supplies for AURUM’s diagnostic network and other clinics.

B2C · B2G

Diagnostic network

Eight PET/CT scanners with a planned capacity of more than 4,000 patients a year. The proposed clinical focus spans oncology, cardiology and neurology, with public programmes considered as a potential payment channel.

R&D

Research and education

A platform for applied research, professional training and academic collaboration. This work is intended to develop technology and expertise within the cluster.

AI · Telemedicine

Digital health

Planned capabilities include AI-assisted image analysis, a digital diagnostic archive and remote consultations. These tools are intended to support medical professionals and collaboration between them.

Closer to life.

Precision diagnostics, closer to home.

AURUM is conceived to improve access to molecular diagnostics in southern Ukraine. Bringing radiopharmaceutical production and diagnostics into one system is intended to reduce reliance on external supplies and unnecessary travel for patients.

For patients

Diagnostics closer to home and a coordinated examination pathway.

For healthcare systems

Regional capacity, specialist training and the potential to work with public healthcare programmes.

For investors

Participation in medical infrastructure with two planned revenue streams and a phased development approach.

Artistic visualisation — PET/CT
Artistic visualisation

Designed as a whole.

The proposed campus, spanning more than 1,000 m², brings together a cyclotron, radiochemical synthesis laboratory, PET/CT equipment and IT infrastructure. Radiation protection, quality assurance and the necessary authorisations are integral to the implementation plan.

1 000+ m²planned cluster floor area

On-site production

An internal production base is intended to reduce dependence on imported radiopharmaceuticals and improve supply planning.

Clinical infrastructure

A single campus is designed to connect technical capacity with patient pathways and specialist teams.

A connected system

Production, logistics, diagnostics and digital services are planned as interdependent processes.

Odesa is the starting point.

Planned development directions. This illustration does not represent an operating supply network.

300 kmtarget supply radius
  1. Odesa

    The first phase focuses on establishing the production and diagnostic cluster and beginning patient services.

  2. Ukraine

    The next direction is a supply network for other healthcare providers. The presentation sets out a target logistics radius of up to 300 km.

  3. Moldova and Romania

    Further expansion is envisaged through cross-border supplies and collaboration with medical networks, subject to the required authorisations and validation of the logistics model.

Capital that becomes infrastructure.

€80mplanned investment

Planned capital expenditure is allocated across production, diagnostic equipment and campus construction. Each forms a distinct part of one operating system.

35%/€28m

Cyclotron and radiochemistry

A particle accelerator and radiopharmaceutical synthesis laboratory.

45%/€36m

PET/CT and digital infrastructure

Eight scanners, IT systems and planned AI-assisted image analysis modules.

20%/€16m

Campus construction

A specialised facility exceeding 1,000 m², with the required engineering infrastructure.

Planned capital allocation from the investment presentation.

Two streams. One business model.

B2C / B2G

Diagnostic services

The model envisages payments from patients, insurers and, subject to eligibility, public healthcare programmes.

B2B

Radiopharmaceuticals

Supply to other clinics is the second planned revenue stream alongside AURUM’s own diagnostic services.

50%+

modelled margin target

The presentation sets out this target under assumptions relating to internal production and equipment utilisation. It is a modelled benchmark, not a verified operating result or a guarantee of investment returns.

Phased financing

The proposal invites discussion of equity participation and funding in tranches tied to implementation milestones.

Potential exits

An IPO or M&A transaction are considered possible long-term scenarios. Deal structure, terms and timing would be determined separately.

Discuss participation

Medicine. Management. Long-term thinking.

Olha Psarova

Project Lead

A PhD candidate in public administration with a focus on healthcare, holding a master’s degree in business analytics and project management. The presentation also states a medical education and more than 15 years of business experience.

LinkedIn

Research and management experience

The AURUM concept draws on research, business analytics and experience engaging with academic and civil society institutions. These disciplines inform the approach to structuring and developing the project.

European context

The presentation identifies EU4Health, Europe’s Beating Cancer Plan and IAEA and WHO approaches as strategic reference points.

Ukrainian and regional context

The concept relates to Ukraine’s cancer control priorities through 2030 and the Odesa region’s development priorities through 2027, while considering public-private cooperation mechanisms. These are the project’s stated reference points, not confirmation of official endorsement, funding or authorisations.

From concept to operation.

The dates below reproduce the plan in the original presentation. They are not a report of current progress; updated timing and stage status are to be confirmed in project discussions.

  1. April–June 2026

    Preparation

    Investment structuring, campus design, licensing procedures and supplier selection.

  2. July–December 2026

    Infrastructure

    Construction of specialised facilities, equipment procurement and radiopharmaceutical logistics planning.

  3. January–June 2027

    Installation and readiness

    Cyclotron and laboratory installation, staff training, commissioning and required authorisations.

  4. From July 2027

    Launch and development

    Planned start of diagnostic services and B2B supply, followed by digital service development and regional expansion.

The future needs your ambition.

For investors, medical operators and prospective partners. Contact the project lead to discuss the concept, potential participation and next steps.

Contact the project lead

See the complete picture.

The concept, CAPEX allocation, financial model and implementation plan in one document.

Download the brochurePDF · English edition. A translation of the original Ukrainian presentation, including its initial assumptions and implementation schedule.